Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor agonists potentially useful for the treatment of schizophrenia, depression, Parkinson’s and Alzheimer’s disease.